546 related articles for article (PubMed ID: 27031563)
21. Current treatment modalities in diabetic macular edema.
Choragiewicz T; Ozimek M; Nowomiejska K; Koss MJ; Juenemann AGM; Rejdak R
Klin Oczna; 2016 Sep; 117(4):267-270. PubMed ID: 29727116
[TBL] [Abstract][Full Text] [Related]
22. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
23. Aflibercept: A Review of Its Use in Diabetic Macular Oedema.
Keating GM
Drugs; 2015 Jul; 75(10):1153-60. PubMed ID: 26056030
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
25. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
Hussain RM; Ciulla TA
Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
[TBL] [Abstract][Full Text] [Related]
26. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
28. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
29. A review of therapies for diabetic macular oedema and rationale for combination therapy.
Amoaku WM; Saker S; Stewart EA
Eye (Lond); 2015 Sep; 29(9):1115-30. PubMed ID: 26113500
[TBL] [Abstract][Full Text] [Related]
30. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Cai S; Bressler NM
Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
[TBL] [Abstract][Full Text] [Related]
31. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.
Ashraf M; Souka A; Adelman R
Br J Ophthalmol; 2016 Dec; 100(12):1596-1604. PubMed ID: 27231313
[TBL] [Abstract][Full Text] [Related]
32. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
33. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
34. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
35. Essential tremor.
Zesiewicz TA; Kuo SH
BMJ Clin Evid; 2015 Dec; 2015():. PubMed ID: 26678329
[TBL] [Abstract][Full Text] [Related]
36. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
Kakkassery V; Winterhalter S; Joussen AM
Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
[TBL] [Abstract][Full Text] [Related]
37. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
Salam A; DaCosta J; Sivaprasad S
Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
[TBL] [Abstract][Full Text] [Related]
38. Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
Nicholson L; Patrao NV; Ramu J; Vazquez-Alfageme C; Muwas M; Rajendram R; Hykin PG; Sivaprasad S
Eye (Lond); 2017 Sep; 31(9):1358-1364. PubMed ID: 28452992
[TBL] [Abstract][Full Text] [Related]
39. Treatment options for diffuse diabetic macular edema.
Bandello F; Iacono P; Battaglia Parodi M
Eur J Ophthalmol; 2011; 21 Suppl 6():S45-50. PubMed ID: 23264328
[TBL] [Abstract][Full Text] [Related]
40. [Choice of treatment for diabetic macular edema].
Yang L; Zhang J
Zhonghua Yan Ke Za Zhi; 2017 Oct; 53(10):724-728. PubMed ID: 29050184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
